The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has...

India has the world's highest TB burden-- 2.6 million active cases and close to 450,000 deaths each year from the infectious bacterial dise...

TB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering h...

BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB...

The Drug Controller General of India (DCGI) has approved Pretomanid for conditional access under the National Tuberculosis Elimination Prog...

Pretomanid, a new oral treatment is a shorter more convenient option for people with extensively drug resistant (XDR) TB. The dossier for g...

A global non-profit drug developer TB Alliance has tied up with domestic company Macleods Pharmaceuticals to develop and commercialise its ...

Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylans global president and executive...

Pretomanid is the third TB drug to have been approved by the USFDA in the last 40 years.

Pretomanid, a new chemical entity, was under development since 2002 by the TB Alliance.

Generic manufacturers are essential players in the fight to end TB so we do speak with generic manufacturers as part of our access strategy.